Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Predicting recurrence patterns and outcomes following resection of pancreatic ductal adenocarcinoma: a contemporary real-world data cohort study.

Annals of medicine and surgery (2012)·2026
Same author

Trends in lung cancer incidence and stage at diagnosis in Singapore: a population-based joinpoint regression analysis by age, sex, and smoking status.

The Lancet regional health. Western Pacific·2026
Same author

Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registry.

Journal of gastrointestinal oncology·2025
Same author

Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity.

Molecular cancer therapeutics·2025
Same author

MMPs and NETs are detrimental in CNS-tuberculosis with MMP Inhibition in CNS-tuberculosis mice improving survival.

Journal of neuroinflammation·2025

相关实验视频

Updated: Jan 16, 2026

Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models
08:43

Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models

Published on: January 14, 2020

11.9K

在胰腺癌中的功能精度:用患者衍生器官重新定义生物标志物

Claire Alexandra Chew1,2, Cheng Mun Wun1,2, Yi Fang Lee1,2

  • 1Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore.

International journal of molecular sciences
|September 27, 2025
PubMed
概括

胰腺癌研究需要更好的生物标志物. 患者衍生器官 (PDO) 为功能精密医学提供了一个动态的平台,改善胰腺管道腺癌 (PDAC) 的治疗策略.

关键词:
生物标志物 生物标志物化学敏感性 化学敏感性胰腺管道腺癌瘤患者获得的有机体精准医学是一门精准医学.

更多相关视频

Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
07:31

Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

Published on: May 26, 2023

6.1K
Organotypic Slice Cultures as Preclinical Models of Tumor Microenvironment in Primary Pancreatic Cancer and Metastasis
09:19

Organotypic Slice Cultures as Preclinical Models of Tumor Microenvironment in Primary Pancreatic Cancer and Metastasis

Published on: June 22, 2021

3.2K

相关实验视频

Last Updated: Jan 16, 2026

Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models
08:43

Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models

Published on: January 14, 2020

11.9K
Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
07:31

Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

Published on: May 26, 2023

6.1K
Organotypic Slice Cultures as Preclinical Models of Tumor Microenvironment in Primary Pancreatic Cancer and Metastasis
09:19

Organotypic Slice Cultures as Preclinical Models of Tumor Microenvironment in Primary Pancreatic Cancer and Metastasis

Published on: June 22, 2021

3.2K

科学领域:

  • 在瘤学瘤学.
  • 生物标志物发现发现
  • 翻译医学是一种翻译医学.

背景情况:

  • 胰腺癌,特别是胰腺管腺癌 (PDAC),尽管治疗进展,预后不佳.
  • 目前的分子亚型对于实时治疗决策缺乏临床实用性.
  • 迫切需要PDAC的临床可行的生物标志物.

研究的目的:

  • 审查当前PDAC生物标志物策略的局限性.
  • 通过使用患者衍生器官 (PDO) 提出生物标志物开发的功能重构.
  • 突出PDO在推进PDAC的精密医学方面的潜力.

主要方法:

  • 关于PDAC生物标志物和患者衍生器官的当前文献的综述.
  • 探索PDO应用的四个关键领域:药物反应表型,模拟化学抵抗,结合瘤微环境和功能概况 (蛋白质学,代谢学).

主要成果:

  • 目前的亚型分类提供了有限的预后价值,并不能有效指导治疗.
  • 患者衍生有机体 (PDO) 作为捕捉临床相关生物学的动态平台.
  • 产品标志允许功能性分析,包括药物反应,化学抵抗和瘤微环境相互作用.

结论:

  • 患者衍生器官 (PDO) 是PDAC中生物标志物开发的一个有前途的功能性方法.
  • PDOs促进了从静态瘤化身到个性化医学的动态平台的转变.
  • 使用PDO的功能精密医学可能会导致胰腺癌的更为定制和有效的治疗策略.